

References

S-213

1. Reston JT, Uhl S, Treadwell JR et al. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. *Mult Scler* 2011; 17(2):204-13.
2. Milanetti F, Bucha J, Testori A et al. Autologous hematopoietic stem cell transplantation for systemic sclerosis. *Curr Stem Cell Res Ther* 2011; 6(1):16-28.
3. Burt RK, Shah SJ, Dill K et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial. *Lancet*. 2011; 378(9790):498-506.
4. Hasselblatt P, Drogitz K, Pothoff K, et al. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. *Alimentary Pharmacology and Therapeutics*. 2012; 36(8):725-35.
5. Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. *American Society of Hematology Education Program*. 2011;(1):280-284.
6. Holloman JP, Ho CC, Hukki A, et al. The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis. *American Journal of Stem Cells*. 2013; (2):95-107.
7. Kim N, Cho SG. Clinical applications of mesenchymal stem cells. *Korean Journal of Internal Medicine*. 2013; 28:387-402.
8. Tyndall A. Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases. *Pediatric Research*. 2012; 1(4): 433-438.
9. InterQual® Level of Care Criteria 2015. Acute Care Adult. McKesson Health Solutions, LLC. 2015; INPT-18.
10. Bakhuraysah M, Siatskas C, Petratos S. Hematopoietic stem cell transplantation for multiple sclerosis: Is it a clinical reality? *Stem Cell Res Ther*. 2016; 7: 12.
11. Malmegrim K, Azevedo J, Amuda L, et al. Immunological balance is associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes. *Front Immunol*. 2017; 8: 167.
12. Farge D, Arruda L, Brigant F, et al. Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. *J Hematol Oncol*. 2017; 10: 21.
13. Mancardi GL, Sormani MP, Gioia M Di, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. *Multiple Sclerosis Journal*. 2012;18(6) 835–842.
14. Muraro PA, Pasquini M, Atkins HL, et al. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. *JAMA Neurol*. 2017;74(4):459-469.
15. Atkins HL, Bowman M, Allan D., et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. *Lancet*. 2016;576-585.

16. Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis; A phase II trial. *Neurology*. 2015;84:981–988.
17. van Laar JM, Naraghi K, Tyndall A. Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. *Rheumatology (Oxford)*. 2015;54(12):2126-2133.
18. van Laar JM, Farge D, Sont JK, et al. Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial. *JAM*. 2014;311(24):2490-2498.
19. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial. *Lancet*. 2011; 378: 498–506.
20. Hayes, Inc. Hayes Health Technology Brief. High-Dose Immunosuppressive Therapy with Hematopoietic Transplantation for Treatment of Multiple Sclerosis. Lansdale, PA: Hayes, Inc.; January, 2018.
21. Hayes, Inc. Hayes Health Technology Brief. High-Dose Immunosuppressive Therapy with Hematopoietic Stem Cell Transplantation for the Treatment of Systemic Sclerosis. Lansdale, PA: Hayes, Inc.; February, 2018.
22. JA Snowden, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplantation*. 2012;47:770–790.